BOSTON — July 20, 2023 — PathAI, a leading provider of AI-powered pathology tools to advance precision medicine, today announced the availability of AIM-HER2 Breast Cancer [i] for research use by clinical laboratories, researchers, and drug developers.

May 1, 2024 · "The PathAI Diagnostics laboratory in Memphis will allow Quest to accelerate its digital journey with an already digitized laboratory." According to the American Cancer Society, 2024 will be the first year that the United States expects more than 2 million new cases of cancer.

BOSTON, MA – November 7, 2022 – PathAI, a leading provider of AI-powered pathology tools to advance precision medicine, today announced that the organization’s recent research will be presented at the Society for Immunotherapy of Cancer’s 37th annual meeting (SITC), which will be held in Boston, MA from November 8-12, 2022. PathAI will ...

Apr 4, 2023 · It is currently available for breast cancer, colorectal cancer, gastric cancer, melanoma, non-small cell lung cancer, pancreatic cancer, prostate cancer, and renal cell carcinoma, with more indications planned to launch later …

Dec 14, 2023 · In addition to identifying cases and slides likely to contain tumor, the product generates overlay visualizations and slide-level quantifications to facilitate pathologist review. PathAI will be expanding this pilot across its network of 50+ laboratory and early access partners across diverse tumor types globally.

BOSTON — March 9, 2023 — PathAI, a global leader in AI-powered pathology, today announced the launch of AISight TM, PathAI’s digital pathology platform, and the AIM-PD-L1 NSCLC RUO algorithm 1, which quantitates the percent of PD-L1 positive tumor and immune cells in non-small cell lung cancer (NSCLC) samples across the whole slide image ...

Boston, MA – January 30, 2024 – PathAI, a global leader in AI-powered pathology, today announced the launch of six additional oncology indications for PathExplore TM, the world’s first structured, standardized and scalable panel for characterization of the tumor microenvironment (TME) from hematoxylin and eosin (H&E)-stained whole-slide ...

Dec 5, 2023 · Indications: Breast Cancer; Clones: Ventana 4B5 and Dako HercepTest ™ Scanners: Leica Aperio® AT2 and GT450; Hamamatsu NanoZoomer® s360; Inputs: Breast cancer biopsy, resection, and/or excision sample from primary, recurrent, or metastatic tumor (excluding in situ tumor)

Apr 8, 2022 · Our research has fueled exciting developments across the oncology landscape including melanoma, hepatocellular carcinoma, head & neck, gastric, colorectal, prostate, and urothelial cancers. We are continuing to expand our research and …

Apr 25, 2024 · At PathAI, we’re dedicated to improving patient outcomes with reliable AI-Powered technology and meaningful collaboration with biopharma and pathology laboratories — aiming to provide invaluable insights for biomarker discovery and drug development, and to improve laboratory workflows.